The Joint Stock Forecast, Price & News

-9.35 (-8.81 %)
(As of 09/20/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume184,862 shs
Average Volume221,477 shs
Market Capitalization$1.39 billion
P/E Ratio82.75
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive JYNT News and Ratings via Email

Sign-up to receive the latest news and ratings for The Joint and its competitors with MarketBeat's FREE daily newsletter.

The Joint logo

About The Joint

The Joint Corp. (United States) engages in the development, ownership, operation, support and management of chiropractic clinics. It operates through two segments: Corporate Clinics and Franchise Operations. The Corporate Clinics segment comprises of the operating activities of the company owned or managed clinics. The Franchise Operations segment includes the operating activities of the franchise business unit. The Joint was founded by Fred Gerretzen, Charles Barnwell, John Leonesio, Todd Welker, Barbara Holland, Steven P. Colmar, Craig P. Colmar and Richard Rees on March 10, 2010 and is headquartered in Scottsdale, AZ.


Joint Insider Sold Over $2.02 Million In Company Stock
Joint Insider Sold Over $2.02 Million In Company Stock
September 16, 2021 |
2 Stocks I Bought Last Week
2 Stocks I Bought Last Week
September 16, 2021 |
Why Should You Hold Centene (CNC) in Your Portfolio Now?
Why Should You Hold Centene (CNC) in Your Portfolio Now?
September 15, 2021 |
The Joint (NASDAQ:JYNT) Shares Gap Up to $102.34
The Joint (NASDAQ:JYNT) Shares Gap Up to $102.34
September 14, 2021 |
The Joint (NASDAQ:JYNT) Sets New 52-Week High at $108.45
The Joint (NASDAQ:JYNT) Sets New 52-Week High at $108.45
September 2, 2021 |
The Joint (NASDAQ:JYNT) Shares Gap Up to $93.65
The Joint (NASDAQ:JYNT) Shares Gap Up to $93.65
August 30, 2021 |
Joint (NASDAQ:JYNT) Could Easily Take On More Debt
Joint (NASDAQ:JYNT) Could Easily Take On More Debt
August 19, 2021 |
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.46 out of 5 stars

Medical Sector

283rd out of 1,352 stocks

Patent Owners & Lessors Industry

5th out of 12 stocks

Analyst Opinion: 3.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

The Joint (NASDAQ:JYNT) Frequently Asked Questions

Is The Joint a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for The Joint in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" The Joint stock.
View analyst ratings for The Joint
or view top-rated stocks.

What stocks does MarketBeat like better than The Joint?

Wall Street analysts have given The Joint a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but The Joint wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting The Joint?

The Joint saw a decline in short interest in the month of August. As of August 13th, there was short interest totaling 819,600 shares, a decline of 19.6% from the July 29th total of 1,020,000 shares. Based on an average trading volume of 346,500 shares, the short-interest ratio is currently 2.4 days. Approximately 5.9% of the shares of the stock are short sold.
View The Joint's Short Interest

When is The Joint's next earnings date?

The Joint is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for The Joint

How were The Joint's earnings last quarter?

The Joint Corp. (NASDAQ:JYNT) released its earnings results on Thursday, August, 5th. The company reported $0.18 EPS for the quarter, beating the Zacks' consensus estimate of $0.05 by $0.13. The company earned $20.22 million during the quarter, compared to analyst estimates of $17.58 million. The Joint had a net margin of 24.55% and a trailing twelve-month return on equity of 41.46%.
View The Joint's earnings history

How has The Joint's stock price been impacted by COVID-19?

The Joint's stock was trading at $13.61 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, JYNT shares have increased by 611.4% and is now trading at $96.82.
View which stocks have been most impacted by COVID-19

What guidance has The Joint issued on next quarter's earnings?

The Joint issued an update on its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $77 million-$79 million, compared to the consensus revenue estimate of $75.85 million.

What price target have analysts set for JYNT?

6 equities research analysts have issued 12-month target prices for The Joint's stock. Their forecasts range from $54.00 to $150.00. On average, they anticipate The Joint's share price to reach $107.00 in the next year. This suggests a possible upside of 10.5% from the stock's current price.
View analysts' price targets for The Joint
or view top-rated stocks among Wall Street analysts.

Who are The Joint's key executives?

The Joint's management team includes the following people:
  • Peter D. Holt, President, Chief Executive Officer & Director
  • Jorge Armenteros, Vice President-Operations
  • Jacob Singleton, Chief Financial Officer & Controller
  • Manjula Sriram, Vice President-Information Technology
  • Steve Knauf, Executive Director-Chiropractic & Compliance

What is Peter D. Holt's approval rating as The Joint's CEO?

87 employees have rated The Joint CEO Peter D. Holt on Peter D. Holt has an approval rating of 59% among The Joint's employees. This puts Peter D. Holt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of The Joint's key competitors?

What other stocks do shareholders of The Joint own?

Based on aggregate information from My MarketBeat watchlists, some companies that other The Joint investors own include Aurora Cannabis (ACB), Advanced Micro Devices (AMD), Raytheon Technologies (RTX), (CRM), Mastercard (MA), Starbucks (SBUX), Twitter (TWTR), Viking Therapeutics (VKTX), AbbVie (ABBV) and Adobe (ADBE).

When did The Joint IPO?

(JYNT) raised $20 million in an IPO on Tuesday, November 11th 2014. The company issued 3,000,000 shares at $6.50 per share. Roth Capital Partners and Feltl and Company acted as the underwriters for the IPO and Sanders Morris Harris was co-manager.

What is The Joint's stock symbol?

The Joint trades on the NASDAQ under the ticker symbol "JYNT."

Who are The Joint's major shareholders?

The Joint's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.16%), FMR LLC (7.23%), Vanguard Group Inc. (6.32%), Next Century Growth Investors LLC (3.29%), State Street Corp (3.00%) and Skylands Capital LLC (2.87%). Company insiders that own The Joint stock include Bandera Partners Llc, Glenn J Krevlin, Jake Singleton, James H Amos Jr, Matthew E Rubel, Matthew E Rubel and Ronald V Davella.
View institutional ownership trends for The Joint

Which major investors are selling The Joint stock?

JYNT stock was sold by a variety of institutional investors in the last quarter, including SW Investment Management LLC, General Equity Holdings LP, Next Century Growth Investors LLC, Wasatch Advisors Inc., Grandeur Peak Global Advisors LLC, First Light Asset Management LLC, AWM Investment Company Inc., and Scholtz & Company LLC. Company insiders that have sold The Joint company stock in the last year include Bandera Partners Llc, Glenn J Krevlin, Jake Singleton, James H Amos Jr, Matthew E Rubel, and Ronald V Davella.
View insider buying and selling activity for The Joint
or view top insider-selling stocks.

Which major investors are buying The Joint stock?

JYNT stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Invesco Ltd., Vanguard Group Inc., State Street Corp, Dimensional Fund Advisors LP, Principal Financial Group Inc., Millennium Management LLC, and Wolverine Trading LLC. Company insiders that have bought The Joint stock in the last two years include Bandera Partners Llc, and Jake Singleton.
View insider buying and selling activity for The Joint
or or view top insider-buying stocks.

How do I buy shares of The Joint?

Shares of JYNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is The Joint's stock price today?

One share of JYNT stock can currently be purchased for approximately $96.82.

How much money does The Joint make?

The Joint has a market capitalization of $1.39 billion and generates $58.68 million in revenue each year. The company earns $13.17 million in net income (profit) each year or $0.30 on an earnings per share basis.

How many employees does The Joint have?

The Joint employs 325 workers across the globe.

What is The Joint's official website?

The official website for The Joint is

Where are The Joint's headquarters?

How can I contact The Joint?

The Joint's mailing address is 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260. The company can be reached via phone at (480) 245-5960 or via email at [email protected].

This page was last updated on 9/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.